The Klein Law Firm
NEW YORK, NY / ACCESSWIRE / July 20, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Home Point Capital Inc. (NASDAQ:HMPT)
This lawsuit is on behalf of all persons and entities other than Defendants that purchased or otherwise acquired Home Point common stock pursuant and/or traceable to the Company's January 29, 2021 initial public offering.
Lead Plaintiff Deadline: August 20, 2021
During the class period, Home Point Capital Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Home Point's aggressive expansion of its broker partners would dramatically increase the Company's expenses; (ii) the mortgage industry was anticipating industry-wide decreased gain-on-sale margins as a result of rising interest rates in 2021 and Home Point would be subject to the same competitive pressures; (iii) accordingly, the Company had overstated its business and financial prospects; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.
Learn about your recoverable losses in HMPT: https://www.kleinstocklaw.com/pslra-1/home-point-capital-inc-loss-submission-form?id=17806&from=1
CarLotz, Inc. (NASDAQ:LOTZ)
Class Period: December 30, 2020 - May 25, 2021
Lead Plaintiff Deadline: September 7, 2021
The LOTZ lawsuit alleges CarLotz, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) due to a surge in inventory during the second half of fiscal 2020, CarLotz was experiencing a "logjam" resulting in slower processing and higher days to sell; (2) as a result, the Company's gross profit per unit would be negatively impacted; (3) to minimize returns to the corporate vehicle sourcing partner responsible for more than 60% of CarLotz's inventory, the Company was offering aggressive pricing; (4) as a result, CarLotz's gross profit per unit forecast was likely inflated; (5) this Company's corporate vehicle sourcing partner would likely pause consignments to the Company due to market conditions, including increasing wholesale prices; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in LOTZ: https://www.kleinstocklaw.com/pslra-1/carlotz-inc-loss-submission-form?id=17806&from=1
Renovacare, Inc. (OTC PINK:RCAR)
Class Period: August 14, 2017 - May 28, 2021
Lead Plaintiff Deadline: September 14, 2021
The RCAR lawsuit alleges that throughout the class period, Renovacare, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) at the direction of Harmel Rayat, RenovaCare engaged in a promotional campaign to issue misleading statements to artificially inflate the Company's stock price; (2) when the OTC Markets inquired, RenovaCare and Mr. Rayat issued a materially false and misleading press release claiming that no director, officer, or controlling shareholder had any involvement in the purported third party's promotional materials; (3) as a result of the foregoing, the Company's disclosure controls and procedures were defective; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in RCAR: https://www.kleinstocklaw.com/pslra-1/renovacare-inc-loss-submission-form?id=17806&from=1
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/656281/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-HMPT-LOTZ-and-RCAR
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Ecological Threat Report 2025: Extreme Wet-Dry Seasons Emerge as Critical Conflict Catalyst29.10.2025 06:00:00 CET | Press release
Approximately 2 billion people - one quarter of humanity - now live in regions experiencing moderate to severe increases in seasonality LONDON, GB / ACCESS Newswire / October 29, 2025 / New research from the Institute for Economics & Peace reveals that changing rainfall patterns are significantly amplifying conflict risks worldwide. The 2025 Ecological Threat Report (ETR), released today, finds conflict death rates are substantially higher in areas where rainfall is concentrating into fewer months, compared to regions where rain is spreading more evenly throughout the year.Ecological Threat Report 2025 Analysing Ecological Threats, Resilience & Peace Key Findings On average in areas where wet and dry seasons are becoming more extreme, there are four times as many conflict deaths as areas where it has decreased. In 2024, natural hazards triggered 45 million short-term internal displacements across 163 countries, the highest figure since at least 2008. Western Brazil, including parts of
Karbon-X Celebrates Major Milestone in Senegal Mangrove Restoration Project28.10.2025 13:00:00 CET | Press release
Planting completed across 7,000 hectares in partnership with Woodside Energy, advancing community-led climate action. DAKAR, SN / ACCESS Newswire / October 28, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is proud to announce a significant milestone in its ABC Mangrove Project, one of West Africa's largest community-led restoration initiatives with the successful completion of planting across more than 7,000 hectares of mangroves along Senegal's coastline. Developed through ALLCOT, Karbon-X's project development and advisory arm (ALLCOT-A Karbon-X Company), and in partnership with Woodside Energy, the project is helping restore critical blue-carbon ecosystems that protect biodiversity, strengthen local economies, and capture carbon naturally from the atmosphere. Through this multi-year effort, thousands of local community members have been engaged in the planting and care of mangroves, creating new jobs, skills training, and sustainable income opportunities for wome
Florence Healthcare Launches SiteLink on AWS Marketplace, Extending its Clinical Trial Operations Platform Capabilities to Cloud28.10.2025 13:00:00 CET | Press release
ATLANTA, GEORGIA / ACCESS Newswire / October 28, 2025 / Florence Healthcare, the leading clinical trial platform connecting pharmaceutical sponsors and research sites worldwide, announced today that SiteLink, a key offering of Florence's Trial Operations Platform, is now available in AWS Marketplace. SiteLink accelerates study startup and enables real-time document distribution, monitoring, and data exchange with study sites, addressing the critical digital divide in clinical trials. With only 30% of global research sites currently using digital workflows, SiteLink helps bridge this gap by automating sponsor-site operational workflows. Bringing the Florence Trial Operations Platform Benefits to AWS As a core component of Florence's Trial Operations Platform, SiteLink delivers the same proven results that have made Florence the #1 clinical trial management solution for six consecutive years. The platform enables: Faster Startup: Up to 70% faster study activation timelines through automa
GoodData Brings AI-Native Data Intelligence to Financial Services28.10.2025 10:00:00 CET | Press release
Embeddable, compliant, and auditable AI agents unlock trusted automation for banks, insurers, and financial institutions. SAN FRANCISCO, CA / ACCESS Newswire / October 28, 2025 / GoodData, a leading analytics and data intelligence company, today unveiled new finance-focused applications for its composable AI platform, designed to tackle the industry's toughest challenges. By combining its AI Lake, AI Hub, and AI Apps into a single foundation for enterprise data intelligence, the next-generation platform gives financial institutions powerful tools to build and deploy AI agents. These agents can detect and investigate fraud in seconds with audit trails regulators can trust, keeping portfolios compliant in real time within industry guidelines. This streamlines regulatory reporting by compiling, checking, and submitting disclosures transparently, all while meeting strict standards for financial compliance, governance, and security. Purpose-built for finance The financial services sector fa
Cambridge Isotope Laboratories, Inc. Unveils ISOAPI-D - a New Standard in Deuterated Reagents for Pharmaceutical Innovation - at CPhI Frankfurt 202527.10.2025 14:00:00 CET | Press release
With ISOAPI-D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents - manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-D ISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics "ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
